Paratek’s Seysara (sarecycline) Receives FDA’s Approval for Treatment of Moderate to Severe Acne
Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM
Shots:
- The approval is based on P-III study results assessing Seysar (sarecycline) in patients with inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older
- The study resulted in safe and effective results in P-III study in patients with moderate to server acne
- Seysara (sarecycline) is a qd, PO, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of moderate to severe acne
Click here to read full press release/ article | Ref: Paratek | Image: Twitter